{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:44:11Z","timestamp":1760132651926,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016304","name":"Medtronic Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ahj.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T01:13:39Z","timestamp":1631582019000},"page":"77-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effect of intensive versus limited monitoring on clinical trial conduct and outcomes: A randomized trial"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6937-4041","authenticated-orcid":false,"given":"Neel M.","family":"Butala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4444-0943","authenticated-orcid":false,"given":"Changyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-724X","authenticated-orcid":false,"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2021.09.002_bib0001","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/cts.12834","article-title":"Remote Monitoring in Clinical Trials During the COVID-19 Pandemic","volume":"13","author":"Izmailova","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ahj.2021.09.002_bib0002","unstructured":"International council for harmonisation of technical requirements for pharmaceuticals for human use. \"Integrated addendum to ICH E6 (R1): Guideline for good clinical practice E6 (R2).\" 2016. Accessed from:https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed at: August 20, 2020."},{"key":"10.1016\/j.ahj.2021.09.002_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/qaj.433","article-title":"Quality assurance within the scope of good clinical practice (GCP)\u2014what is the cost of GCP-related activities? A survey within the Swedish association of the pharmaceutical industry (LIF)'s members","volume":"12","author":"Funning","year":"2009","journal-title":"Qual Assur J"},{"key":"10.1016\/j.ahj.2021.09.002_bib0004","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ahj.2004.04.049","article-title":"Reducing the costs of phase III cardiovascular clinical trials","volume":"149","author":"Eisenstein","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2021.09.002_bib0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1740774507087704","article-title":"Specific barriers to the conduct of randomized trials","volume":"5","author":"Duley","year":"2008","journal-title":"Clinical trials (London, England)"},{"key":"10.1016\/j.ahj.2021.09.002_bib0006","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/1740774511402703","article-title":"Monitoring the quality of conduct of clinical trials: a survey of current practices","volume":"8","author":"Morrison","year":"2011","journal-title":"Clinical trials (London, England)"},{"key":"10.1016\/j.ahj.2021.09.002_bib0007","unstructured":"US Food and Drug Administration. FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic: guidance for industry, investigators, and institutional review boards [Updated on January 27, 2021]\". Accessed from: https:\/\/www.fda.gov\/media\/136238\/download. Accessed at: March 6, 2021."},{"key":"10.1016\/j.ahj.2021.09.002_bib0008","unstructured":"European Medicines Agency. Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic [Version 4]\" Available at: Accessed from:https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-10\/guidanceclinicaltrials_covid19_en.pdf. Accessed at: March 6, 2021."},{"key":"10.1016\/j.ahj.2021.09.002_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1740774519881616","article-title":"A randomized evaluation of on-site monitoring nested in a multinational randomized trial","volume":"17","author":"Wyman Engen","year":"2020","journal-title":"Clin Trials"},{"key":"10.1016\/j.ahj.2021.09.002_bib0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/1740774517724165","article-title":"Risk-adapted monitoring is not inferior to extensive on-site monitoring: results of the ADAMON cluster-randomised study","volume":"14","author":"Brosteanu","year":"2017","journal-title":"Clin Trials"},{"key":"10.1016\/j.ahj.2021.09.002_bib0011","article-title":"OPTIMON: First results of the French tiral on optimisation of monitoring","author":"Journot","year":"2015","journal-title":"EpiClin, Montpellier"},{"key":"10.1016\/j.ahj.2021.09.002_bib0012","doi-asserted-by":"crossref","first-page":"e51623","DOI":"10.1371\/journal.pone.0051623","article-title":"The value of source data verification in a cancer clinical trial","volume":"7","author":"Tudur Smith","year":"2012","journal-title":"PloS one"},{"key":"10.1016\/j.ahj.2021.09.002_bib0013","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jacc.2012.09.001","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document","volume":"60","author":"Kappetein","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.09.002_bib0014","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ahj.2021.09.002_bib0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ahj.2019.02.007","article-title":"Validating the use of registries and claims data to support randomized trials: rationale and design of the extending trial-based evaluations of medical therapies using novel sources of data (EXTEND) study","volume":"212","author":"Strom","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2021.09.002_bib0016","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.ahj.2021.09.002_bib0017","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jcin.2020.03.049","article-title":"Validation of administrative claims to ascertain outcomes in pivotal trials of transcatheter aortic valve replacement","volume":"13","author":"Butala","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2021.09.002_bib0018","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00228-015-2004-y","article-title":"The impact of clinical trial monitoring approaches on data integrity and cost\u2013a review of current literature","volume":"72","author":"Olsen","year":"2016","journal-title":"Eur J Clin Pharmacol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321002301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321002301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:07:39Z","timestamp":1757570859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870321002301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":18,"alternative-id":["S0002870321002301"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2021.09.002","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of intensive versus limited monitoring on clinical trial conduct and outcomes: A randomized trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}